Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 44 clinical trials
BREntuximab Vedotin in SEcond LIne Therapy BEfore Transplant

A Randomized Phase IIb Study, Evaluating Efficacy of Salvage Therapy with Brentuximab Vedotin-ESHAP vs ESHAP in Patients with Relapsed / Refractory Classical Hodgkin's Lymphoma, Followed by

  • 0 views
  • 27 Jan, 2021
  • 19 locations
Brentuximab Vedotin and Nivolumab for the Treatment of Patients With Relapsed Classical Hodgkin Lymphoma

This phase II trial investigates how well brentuximab vedotin and nivolumab work in treating patients with classical Hodgkin lymphoma that has come back (relapsed). Brentuximab vedotin is a

  • 0 views
  • 25 Mar, 2022
  • 1 location
Consolidation Therapy With Brentuximab Vedotin After Allogeneic Stem Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma

therapy by Brentuximab Vedotin (BV) for up to one year. The primary objective of the trial is to show efficacy of the experimental consolidative treatment strategy. Secondary objectives are to

  • 0 views
  • 26 Jan, 2021
  • 1 location
Brentuximab Vedotin in Early Stage Hodgkin Lymphoma (RADAR)

Eligible patients will be randomised to receive either ABVD or A2VD chemotherapy. An interim PET-CT scan will be performed after 2 cycles of treatment, which will be used to adapt subsequent treatment. Patients will receive a total of 3-4 cycles of chemotherapy and may also receive involved site radiotherapy as …

  • 0 views
  • 06 May, 2022
  • 3 locations
Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma

anticancer drug (brentuximab vedotin) and three chemotherapy drugs (doxorubicin, vinblastine, and dacarbazine). These four drugs are called "A+AVD." Participants will be treated with granulocyte colony

measurable disease
dacarbazine
white blood cell count
vinblastine
doxorubicin
  • 44 views
  • 05 May, 2022
  • 68 locations
Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL (ECHELON-3)

Participants in this study will have diffuse large B-cell lymphoma (DLBCL) that has come back or not gotten better with treatment. The trial will study whether brentuximab vedotin plus two drugs

measurable disease
avid
rituximab
lenalidomide
brentuximab
  • 6 views
  • 06 May, 2022
  • 115 locations
Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma

This phase III trial compares immunotherapy drugs (nivolumab or brentuximab vedotin) when given with combination chemotherapy in treating patients with newly diagnosed stage III or IV classic

nivolumab
human immunodeficiency virus
prednisone
estimated creatinine clearance
vinblastine
  • 101 views
  • 12 May, 2022
  • 326 locations
A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression

This clinical trial will study brentuximab vedotin with CHP to find out if the drugs work for people who have certain types of peripheral T-cell lymphoma (PTCL). It will also find out what side

anaplastic large cell lymphoma
prednisone
measurable disease
adult t-cell leukemia/lymphoma
large cell lymphoma
  • 0 views
  • 11 May, 2022
  • 40 locations
Brentuximab Vedotin for Systemic Sclerosis (BRAVOS)

There is significant unmet need for effective treatment options for Diffuse Cutaneous Systemic Sclerosis (dcSSc). The present study will be a dose-escalation safety trial of brentuximab vedotin

mycophenolate
methotrexate
immunosuppressive agents
rheumatism
MRSS
  • 722 views
  • 29 Jan, 2022
  • 8 locations
Brentuximab Vedotin in Early Diffuse Cutaneous Systemic Sclerosis

The purpose of this study is to assess feasibility, safety and preliminary efficacy of Brentuximab vedotin (Adcetris), a CD30-directed antibody-drug conjugate, in the treatment of active diffuse

  • 68 views
  • 22 Mar, 2022
  • 1 location